logo
AU experts develop compounds that may boost human memory

AU experts develop compounds that may boost human memory

Time of India3 days ago

Prayagraj: In a breakthrough development, scientists from Allahabad University (AU) have identified 14 chemical compounds that could significantly enhance human memory. These compounds, developed in the university's chemistry laboratory, show promising effects in opening constricted brain neurons, which are often associated with memory loss and cognitive decline.
Tired of too many ads? go ad free now
The research, led by Prof Ramendra Kumar Singh of the Department of Chemistry at AU, marks a major advancement in the search for memory-enhancing drugs. Remarkably, the compounds developed in the Prayagraj-based university are currently undergoing international testing in laboratories in the United States, specifically at California State University, Fullerton.
According to Prof Singh, preliminary results from the testing of three compounds showed positive outcomes, suggesting their potential in combating memory-related disorders.
A research paper detailing this discovery was recently published in the Netherlands-based scientific journal, Journal of Molecular Structure, further highlighting the global relevance of this work. Explaining the scientific basis of the study, Prof Singh said that hyperphosphorylated tau proteins—proteins with an excess of phosphate groups—are responsible for memory degradation in humans.
These proteins accumulate in the brain due to a deficiency of a neurotransmitter called acetylcholine.
The enzyme acetylcholinesterase is responsible for breaking down acetylcholine, thus leading to its depletion.
The 14 newly developed compounds aim to inhibit the function of acetylcholinesterase, thereby maintaining healthy acetylcholine levels and potentially improving memory and brain health. To identify these compounds, the research team conducted a series of chemical reactions in the lab and utilised computational techniques such as molecular docking and computer simulation to evaluate the compounds' activity and cytotoxicity.
Tired of too many ads? go ad free now
The detailed analysis confirmed that all 14 compounds showed significant promise in both effectiveness and safety. These compounds, after being encoded, were sent to California for second-phase testing on specific cell lines known to produce the tau protein responsible for Alzheimer's disease. Although the names of the compounds have not yet been disclosed, Prof Singh noted that the early-stage results are encouraging, with three compounds already delivering positive findings. The next steps in the research include developing a drug based on the most effective molecule. If successful, this could lead to a new therapeutic option for millions suffering from memory loss and neurodegenerative conditions like Alzheimer's.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Zydus acquires US biologics manufacturing facilities, Manufacturing News, ET Manufacturing
Zydus acquires US biologics manufacturing facilities, Manufacturing News, ET Manufacturing

Time of India

timean hour ago

  • Time of India

Zydus acquires US biologics manufacturing facilities, Manufacturing News, ET Manufacturing

Advt Homegrown pharma major Zydus Lifesciences on Tuesday announced it has entered the global biologics contract development and manufacturing ( CDMO ) space with the acquisition of two manufacturing facilities from US-based Agenus Inc. The company will pay $75 million upfront and up to $50 million in milestone-linked payments over three deal gives Zydus control of biologics manufacturing units in Emeryville and Berkeley California , providing immediate access to advanced development and production capabilities. The facilities will be housed under an independent CDMO entity within the group and serve global biotech and pharma firms. Zydus intends to further expand the team and help create new jobs in the region and contribute to the local will also become the exclusive contract manufacturer for Agenus' two Phase 3-ready immuno-oncology candidates-Botensilimab and Balstilimab-for clinical and commercial supply. It has also secured the first right of negotiation to manufacture future Agenus pipeline Sharvil Patel, managing director, Zydus Lifesciences, said, "The acquisition gives Zydus a strategic foothold in the US for biologics manufacturing in the global hub for biotech innovation, California. It will enhance our ability to partner with innovation-centric entities, advancing new products and prioritizing patient-centric solutions. This move strengthens our long-term biologics vision and positions us to better serve the evolving needs of the global biopharmaceutical industry."The deal positions Zydus to benefit from growing global demand for biologics manufacturing, as governments and companies shift supply chains closer to key markets.

Heavy inflows in Godavari put a brake on tests at Medigadda
Heavy inflows in Godavari put a brake on tests at Medigadda

Hans India

timean hour ago

  • Hans India

Heavy inflows in Godavari put a brake on tests at Medigadda

Hyderabad: Heavy inflows in river Godavari may delay the geo technical and other quality tests which are being carried out for the repairs of the damaged three barrages of Medigadda, Sundilla and Annaram. Following the recommendations of the NDSA (National Dam Safety Authority), the State Irrigation wing has made arrangements to conduct the tests at the barrage sites. As a result, the repair works proposed by the government will be hampered for a long time until water levels recede in the river. The Irrigation officials said that considering the NDSA report, the irrigation officials said that the Pune-based Centre for Water and Power Research (CWPRS) has been asked to make some recommendations for tests at the barrages. The research centre suggested to conduct eight tests which includes parallel seismic, geo physical study, metal gates and the status of concrete structures. It requires at least one year to complete all the tests and prepare a report on the entire structure. Officials said that the irrigation officials in consultation with the quality control wing visited the barrages but they could not move forward due to heavy inflows in Godavari under the influence of heavy rains in the monsoon season. 'It takes a lot of time to conduct the tests in view of the requirement of technical expertise and big logistical support. Identifying seepage and the estimation of impact of craters under the raft are the major tasks in the tests'. The authorities said that the seismic tests also required a lot of time. The IMD already predicted heavy rains in the current monsoon and projects under Godavari, which is already receiving good inflows. The technical teams will not conduct the tests unless the barrages are empty and dry. Water storage in the barrages will not give accurate results in the tests.

SRN hosp to install advance machine for cancer treatment
SRN hosp to install advance machine for cancer treatment

Time of India

time3 hours ago

  • Time of India

SRN hosp to install advance machine for cancer treatment

Prayagraj: Swaroop Rani Nehru Hospital, under the Prime Minister's Health Protection Scheme (PMSSY), is set to install an HDR Brachytherapy machine for cancer treatment in the coming months. The project, initially proposed in 2016 as part of a Super Speciality Block, was temporarily shelved due to the COVID-19 pandemic, which redirected all available resources and infrastructure. According to the media in charge of SRN, Dr Santosh Kumar Singh, the medical college will soon procure the machine because the most crucial component—an underground shielded bunker required for its installation—has not been constructed. The layout is now ready, and work on the radiation-safe bunker has been initiated following communication with the state govt. Detailing what Brachytherapy is, Dr Singh said, "Brachytherapy is a highly focused type of internal radiation therapy used for cancers like cervical, prostate, breast and skin cancers. It involves placing a radioactive source directly inside or next to the tumour, thereby delivering a high dose of radiation to the cancer with minimal damage to surrounding healthy tissues." Unlike external beam radiation therapy (EBRT), brachytherapy ensures that the rest of the body is exposed to very little radiation, making it an effective and safe treatment modality. According to experts, "This form of radiation therapy is extremely useful for localised tumours, and once the machine is installed, it will benefit cancer patients across the region." Initially, in 2016, plans were approved to install this machine under PMSSY. By 2019, the Super Speciality Block was completed, but in 2020, during the peak of COVID-19, the building was repurposed into a dedicated COVID ward, postponing all other medical projects. "As of 2025, groundwork for bunker construction has restarted, and layout approvals are in place. Soon we will procure the machine, and the patients here at SRN will be able to get the state-of-the-art facility," said Dr Santosh, who is also the Associate Professor at MLN Medical College.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store